Google
EOLS — EVOLUS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
EOLS FAQ
What is EOLS's P/E ratio?
EVOLUS INC (EOLS) currently trades at a P/E ratio of 3,343.39.
What is EOLS's ROE?
EVOLUS INC reports a Return on Equity (ROE) of 150.87%.
What is EOLS's dividend yield?
EVOLUS INC offers a dividend yield of 0.00%.
What is EOLS's Deepscope Quality Score?
Deepscope rates EOLS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EOLS?
Deepscope's AI Timing Score for EOLS is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EOLS belong to?
EVOLUS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 6.67
Price
0.07
(1.06%)
Day Change
|
|
|---|
EOLS, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.67 |
| PBV / Sector |
-15.10 / 2.76
|
| Earning Per Share | -0.67 |
| PE / Sector |
3,343.39 / 23.64
|
| PEG or PE/Growth / Sector |
-223.94 / 0.13
|
| Average 1M Daily Value |
4.60 M
GREAT
|
| Average 1W Daily Value |
4.84 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:24 |
| Symbol | EOLS |
| Name | EVOLUS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 65.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 434.64 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660
Phone: 949 284 4555
Website: https://www.evolus.com
Employees: 350
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
